Which type of cytokine is used to treat anemia secondary to chronic kidney disease?

Erythropoietin is a critical cytokine utilized in the treatment of anemia associated with chronic kidney disease (CKD). In patients with CKD, the kidneys often produce insufficient levels of erythropoietin, a hormone crucial for the regulation of red blood cell production in the bone marrow. As a result, individuals with CKD commonly experience anemia due to a lack of this hormone.

By administering erythropoietin, clinicians can stimulate the production of red blood cells, thereby alleviating the symptoms associated with anemia, such as fatigue and weakness. This approach not only improves the patient's quality of life but also helps mitigate the risks associated with anemia, such as cardiovascular issues.

Other cytokines mentioned do not serve the same purpose in this context. For example, α-interferon is primarily used in antiviral therapies and certain cancers, interleukin-2 has applications in immunotherapy for cancer, and interleukin-11 is involved in platelet production and has different therapeutic uses. Therefore, erythropoietin stands out as the specific cytokine directly linked to the management of anemia in patients with chronic kidney disease.